Put companies on watchlist
S Immo AG
ISIN: AT0000652250
WKN: 902388
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

S Immo AG · ISIN: AT0000652250 · EQS - Analysts (9 News)
Country: Germany · Primary market: Austria · EQS NID: 21441
29 November 2024 09:06AM

Sell


Original-Research: S Immo AG - from NuWays AG

29.11.2024 / 09:05 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.


Classification of NuWays AG to S Immo AG

Company Name: S Immo AG
ISIN: AT0000652250
 
Reason for the research: Update
Recommendation: Sell
from: 29.11.2024
Target price: EUR 22.05
Last rating change:
Analyst: Philipp Sennewald

Operations on track but delisting ahead

Yesterday, S IMMO released its Q3 results, showing continued strong operations on the back of recent portfolio transactions. Yet, the company also recently announced that 2024 was the last year of S IMMO's shares trading on the Vienna Stock Exchange. In detail: 

Rental income in Q3 increased 38.7% yoy to € 55.8m, which was mainly driven by several major acquisitions in Austria and the Czech Republic. Moreover, the hotel segment grew revenues by 5.6% yoy to € 19.5m, proving a sustainable recovery of the hotel business at S IMMO following Covid.

Yet, FFO I slightly decreased by 2% yoy to € 24.6m, driven by higher operating expenses for the real estate and hotel portfolio as well as increased other OpEx, which is also attributable to an increased acquisition activity compared to the same period last year. On a normalized level, FFO should have slightly increased. The EPRA NTA slightly increased compared to H1 to € 25.31 per share.

Squeeze-out scheduled. On Tuesday, S IMMO sent out a corporate news, stating that the entry of the squeeze-out in the Commercial Court of Vienna is expected for December 3. The squeeze-out will then take effect upon entity, meaning that all shares held by the minority shareholders will be transferred to the main shareholder, IMMOFINANZ AG. From this point on, it will no longer be possible to trade S IMMO AG shares on the stock exchange. The last day of trading in S IMMO AG shares on the Vienna Stock Exchange is therefore expected to be December 2.

According to the resolution of the AGM, affected shareholders will receive a cash compensation to the tune of € 22.05 per share. The settlement will be paid with a value date of December 11. Against this backdrop, we again advise remaining shareholders to sell their shares, especially at current levels above the cash settlement amount, and reiterate our PT of € 22.05 on this basis.

+++ Coverage discontinued +++

You can download the research here: http://www.more-ir.de/d/31441.pdf
For additional information visit our website: www.nuways-ag.com/research

Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++


The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


2040825  29.11.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2040825&application_name=news&site_id=boersengefluester_html
Visual performance / price development - S Immo AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.